Smallpox

Revision as of 22:19, 26 April 2015 by Ostermayer (talk | contribs)

Background

  • Caused by the variola virus[1]
  • Passed through direct contact with the person, with body fluids, as well as with airborne droplets of an infected, symptomatic person
  • Most infectious during the first week of symptoms, but will remain infectious until the last pox scab falls off
  • Humans are the only known host[2]
  • Declared eradicated in 1980 after a global immunization campaign from 1966-1980; last known natural case was in Somalia in 1977; last known cases were in England in 1978 after a laboratory accident[3]

Bioterrorism

  • There are stocks of the virus in 2 laboratories – one in Atlanta, Georgia, USA and one in Moscow, Russia
  • There are concerns some laboratories may illegally have the virus and could release it as a weapon of bioterrorism[4]
    • This was attempted by British soldiers in 1763 by throwing blankets from people with smallpox to the American Indians
  • In July 2014, 2 vials of smallpox were unknowingly discovered at the National Institutes of Health in Bethesda, Maryland leading to heightened concerns that there may be more stockpiles in the world[5]
  • Many proposals have been made to destroy all the remaining vials of smallpox and related viruses, but as of yet the virus remains in those 2 laboratories

Vaccination History

  • The vaccine “vaccinia variola” was made from a closely-related virus
  • Discovered by Edward Jenner who found out that the milkmaids who had been exposed to cowpox were immune to smallpox
  • Vaccination is considered successful if at least one pustule forms at the injection site
  • Does have serious side effects, especially in the immunocompromised, including death in rare cases
  • Due to the side effects and the current eradication, it is not used anywhere in the world currently
  • Many governments have large stockpiles of the vaccinia vaccine and plans in place for rapid response and vaccination if an outbreak were to occur

Clinical Features

  • Incubation period: 7-19 days
  • Initial phase begins as a fever, fatigue/weakness, dorsal-lumbar pain, myalgias, nausea/vomiting
  • 2-4 days later the characteristic rash appears
    • Worst on the face, arms, legs, and includes the palms and soles
    • Lesions will generally all be at same stage
    • Lesions begin as clear fluid-filled vesicles, progress to pustules, and then harden and form a crust, ultimately falling off in about 3-4 weeks
  • Several different disease courses
    • Variola minor – most common form of the disease, described above
    • Variola fulminans – rapid death during the initial phase
    • Variola confluens – initial maculopapular rash becomes confluent leading to 96% mortality
    • Variola hemorrhagica – hemorrhages occur within the blisters as well as mucus membranes and internal organs, death usually occurs during the first 24 hours
Child with Smallpox

Workup

  • Clinical diagnosis based on symptoms and characteristic rash
  • PCR DNA test
  • When the disease was present, either electron microscopy of stained crusts of lesions or a slide precipitation method was used

Differential Diagnosis

Pediatric Rashes

Pediatric Rash

Treatment

  • IMMEDIATE NOTIFICATION OF PUBLIC HEALTH AUTHORITIES
  • Vaccine administered up to 3 days post-exposure was effective in preventing infection as well as lessening the severity of the disease if infection occurred [6]

Post-Exposure Prophylaxis

  • Vaccinia Vaccine (administer within 72hrs of exposure)

Active Disease

  • Supportive care and wound care for open lesions
  • Vaccinia Vaccine within the first 72hrs can decrease total disease severity and within 7 days may decrease symptoms
    • Vaccination is not efficacious once the patient has developed rash[7]

Vaccinia Vaccine Complications

Contraindications for administration include:

  • Pregnancy
  • Severe cardiac disease
  • Immunocompromise
  • Same living quarters as other person with above contraindications
    • due to viral shedding

Isolation

  • Airborne and contact isolation with negative pressure
  • Personal protective wear level D with N95 respirator


See Also

Bioterrorism

References

</references>

  1. Rosen, Peter, John A. Marx, Robert S. Hockberger, and Ron M. Walls. "Smallpox." Rosen's Emergency Medicine Concepts and Clinical Practice. 8th ed. Vol. 2. Philadelphia, PA: Elsevier/Saunders, 2013. 1579-1580.
  2. Barquet, Nicolau, MD, and Pere Domingo, MD. "Smallpox: The Triumph over the Most Terrible of the Ministers of Death." Annals of Internal Medicine 127 (1997): 635-42.
  3. Ellner, P. D. "Smallpox: Gone but Not Forgotten." Infection 26.5 (1998): 263-69.
  4. Anderson PD. Bokor G. Bioterrorism: pathogens as weapons. J Pharm Pract. 2012 Oct;25(5):521-9.
  5. "Smallpox, Smallpox FAQ." WHO | World Health Organization. http://www.who.int/csr/disease/smallpox/en/ & http://www.who.int/csr/disease/smallpox/faq/en/
  6. Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am. 2008 May;26(2):517-47
  7. Cdc.gov. 2020. Prevention and Treatment | Smallpox | CDC. [online] Available at: <https://www.cdc.gov/smallpox/prevention-treatment/index.html> [Accessed 11 September 2021].